Mesoblast Ltd ADR (MESO) Stock Price, Quote & News

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9639 6036

Fax: 61 3 9639 6030

Website: www.mesoblast.com

Address:

55 Collins Street, Level 38, Melbourne, Australia

trichomy May. 7 at 1:43 PM

$INMB $INMB $KRYS $MESO $NVAX $MRNA There is NO reason why InmuneBio is less than $ 3 right now It is trading at 1.5 right now . Fire sale!!

0 · Reply

trichomy May. 6 at 4:40 PM

$INMB $INMB $ABEO $KRYS $MESO $IBRX We are in the eye of the storm . Volume already way up. This is the calm before tomorrow Booyah! Wake up people! 🔥 🔥 INMB 🔥 🔥

2 · Reply

trichomy May. 5 at 9:38 PM

$INMB $INMB expands collab with Anthony Nolan charity for umbilical cord tissue supply to advance CORDStrom hucMSC platform — targeting RDEB (CORDStrom-col7a), solid tumors (TRAIL), OA & more. Prepping for commercial approval! Strong supply deal + regulatory momentum in hot cell/gene therapy & rare disease space. $ABEO $KRYS $MESO $IBRX #biotech #celltherapy #RDEB https://www.stocktitan.net/news/INMB/i-nmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cord-r715r3sueyi2.html

1 · Reply

BrianRix May. 1 at 11:49 AM

$MESO back to 20s where we belong

0 · Reply

AlertsAndNews Apr. 30 at 2:42 AM

$MESO headline after the AH close. Mesoblast Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

0 · Reply

ClassiTrader Apr. 30 at 12:59 AM

$MESO Mesoblast reported fiscal third-quarter net revenue from Ryoncil of US$30.3 million on gross sales of US$35.3 million. Net operating cash spend narrowed to US$4.1 million, supported by receipts of US$34.6 million. Cash on hand totaled US$122 million at March 31, 2026. Patient recruitment target was reached in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain. Exclusive worldwide license was secured for patented CAR technology platform to develop precision-enhanced MSC products.

0 · Reply

jcooptechit Apr. 29 at 4:04 PM

$CELZ 93% RESPONSE RATE… AND THE MARKET IS STILL ASLEEP ON THIS? CELZ recently dropped a game-changing update that could redefine regenerative medicine. 🧬 Ultrasome (derived from CELZ-201) ▪️ 93% response rate in knee osteoarthritis (pain + mobility improvement) ▪️ ZERO serious adverse events ▪️ Built from GMP-grade CELZ-201: strong platform continuity ▪️ Cell-free, off-the-shelf therapy = scalable + lower cost 💡 What This Means: This isn’t just a trial update… this is validation of a scalable regenerative platform ▪️ From cell therapy: mass-producible biologics ▪️ From niche treatment: commercial opportunity ▪️ Partnerships + expanded clinicals now in focus ⚠️ Knee osteoarthritis is a multi-billion dollar market with limited long-term solutions. 🔥 93% response. Clean safety. Scalable model. How long before the market prices this in??? Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $MESO $FATE $CAPR

2 · Reply

OpenOutcrier Apr. 29 at 12:25 PM

$MESO (+2.5% pre) Mesoblast completes patient recruitment for phase 3 chronic back pain trial https://ooc.bz/l/100328

0 · Reply

AlertsAndNews Apr. 29 at 2:40 AM

$MESO Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain "achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration."

0 · Reply

HedgeFollow Apr. 16 at 4:10 PM

🔍 𝗙𝗥𝗘𝗦𝗛 𝗕𝗨𝗬𝗦 🔎 Among the 𝗟𝗮𝗿𝗴𝗲𝘀𝘁 𝗜𝗻𝘀𝗶𝗱𝗲𝗿 𝗕𝘂𝘆𝘀 in the past week: $NKE - $ 2.2M $LW - $ 6.4M $CHPT - $ 250k $MESO - $ 26.2M Nike being the most notable one especially by who the Insiders were who bought. Source: https://hedgefollow.com/largest-insider-buys.php

0 · Reply

Mesoblast (MESO) Reports Strong Q1 Sales for RyoncilÂ®

Apr 29, 2026, 8:55 PM EDT - 13 days ago

Market Cap	1.88B
Revenue (ttm)	17.20M
Net Income (ttm)	-102.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.84%
Debt to Equity Ratio	0.22

Volume	159,700
Avg Vol	253,102
Day's Range	N/A - N/A
Shares Out	129.46M
Stochastic %K	7%
Beta	2.09
Analysts	Strong Sell
Price Target	$35.00